Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022)

Spyre Therapeutics (SYRE) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $566000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $566000.0, compared with a TTM value of $566000.0 through Dec 2022, changed N/A, and an annual FY2022 reading of $566000.0, changed N/A over the prior year.
  • Long-Term Deferred Tax was $566000.0 for Q4 2022 at Spyre Therapeutics.
  • Across five years, Long-Term Deferred Tax topped out at $566000.0 in Q4 2022 and bottomed at $566000.0 in Q4 2022.